CO2021005768A2 - Anticuerpo fn14 anti–humano - Google Patents

Anticuerpo fn14 anti–humano

Info

Publication number
CO2021005768A2
CO2021005768A2 CONC2021/0005768A CO2021005768A CO2021005768A2 CO 2021005768 A2 CO2021005768 A2 CO 2021005768A2 CO 2021005768 A CO2021005768 A CO 2021005768A CO 2021005768 A2 CO2021005768 A2 CO 2021005768A2
Authority
CO
Colombia
Prior art keywords
human
antibody
seq
amino acid
acid sequence
Prior art date
Application number
CONC2021/0005768A
Other languages
English (en)
Inventor
Misato Ito
Risa Kashiwagi
Masakatsu Kawakami
Original Assignee
Astellas Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astellas Pharma Inc filed Critical Astellas Pharma Inc
Publication of CO2021005768A2 publication Critical patent/CO2021005768A2/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Problema: Se proporciona un anticuerpo Fn14 anti–humano que se une al Fn14 humano para inhibir una acción a través del Fn14 humano, evitando o tratando de este modo la caquexia por cáncer. Medios para la solución: Los inventores han realizado estudios sobre un anticuerpo Fn14 anti–humano y han proporcionado un anticuerpo Fn14 anti–humano que comprende una cadena pesada que consiste en la secuencia de aminoácidos de SEC. ID. NO: 2 y una cadena ligera que consiste en la secuencia de aminoácidos de SEC. ID. NO: 4.
CONC2021/0005768A 2018-10-31 2021-04-30 Anticuerpo fn14 anti–humano CO2021005768A2 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2018205995 2018-10-31
PCT/JP2019/042587 WO2020090892A1 (ja) 2018-10-31 2019-10-30 抗ヒトＦｎ１４抗体

Publications (1)

Publication Number Publication Date
CO2021005768A2 true CO2021005768A2 (es) 2021-05-10

Family

ID=70464144

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2021/0005768A CO2021005768A2 (es) 2018-10-31 2021-04-30 Anticuerpo fn14 anti–humano

Country Status (17)

Country Link
US (1) US20210388096A1 (es)
EP (1) EP3875114A4 (es)
JP (1) JP7415939B2 (es)
KR (1) KR20210084473A (es)
CN (1) CN112930195B (es)
AR (1) AR123671A1 (es)
AU (1) AU2019369771A1 (es)
BR (1) BR112021008424A2 (es)
CA (1) CA3117930A1 (es)
CO (1) CO2021005768A2 (es)
IL (1) IL282650B1 (es)
JO (1) JOP20210093A1 (es)
MA (1) MA54097A (es)
MX (1) MX2021004976A (es)
SG (1) SG11202104463YA (es)
WO (1) WO2020090892A1 (es)
ZA (1) ZA202102879B (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20230131207A (ko) 2021-01-13 2023-09-12 아스텔라스세이야쿠 가부시키가이샤 ActRIIA, ActRIIB 및 Fn14에 결합하는 다중 특이성항체
WO2023062848A1 (en) * 2021-10-14 2023-04-20 Astellas Pharma Inc. Pharmaceutical composition comprising anti-human fnl4 antibody or antigen-binding fragment thereof for preventing or treating cancer

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
DK0690132T3 (da) 1993-03-11 2004-04-13 Chemo Sero Therapeut Res Inst Monoklonalt anti-HIV-antistof
WO2001045730A2 (en) 1999-12-20 2001-06-28 Immunex Corporation Tweak receptor
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
CN102225200A (zh) * 2005-03-07 2011-10-26 健泰科生物技术公司 用于调控tweak和fn14活性的方法和组合物
DK1888113T3 (da) * 2005-05-27 2014-09-01 Biogen Idec Inc Tweak-bindende antistoffer
EP2545938A1 (en) 2007-08-03 2013-01-16 Abbott Biotherapeutics Corp. Therapeutic use of anti-tweak receptor antibodies
BRPI0912198A2 (pt) 2008-05-15 2019-09-24 Biogen Idec Inc anticorpos anti-fn14 e usos dos mesmos
US8093006B2 (en) * 2009-04-02 2012-01-10 Hoffmann-La Roche Inc. Antibodies against human tweak and uses thereof
WO2012122513A2 (en) 2011-03-10 2012-09-13 Omeros Corporation Generation of anti-fn14 monoclonal antibodies by ex-vivo accelerated antibody evolution
SG2014010334A (en) * 2011-08-23 2014-06-27 Transbio Ltd Fn14 binding proteins and uses thereof
JP2016000003A (ja) * 2013-04-19 2016-01-07 アステラス製薬株式会社 新規抗ヒトｔｗｅａｋ抗体
KR20160019434A (ko) 2013-06-14 2016-02-19 바이엘 파마 악티엔게젤샤프트 항-tweakr 항체 및 그의 용도
WO2015006508A2 (en) * 2013-07-09 2015-01-15 The Translational Genomics Research Institute Compositions and methods of screening for compounds that modulate activity at a tweak binding site on a crd of fn14

Also Published As

Publication number Publication date
KR20210084473A (ko) 2021-07-07
AU2019369771A1 (en) 2021-06-03
EP3875114A1 (en) 2021-09-08
AR123671A1 (es) 2023-01-04
EP3875114A4 (en) 2022-08-10
IL282650B1 (en) 2024-05-01
MX2021004976A (es) 2021-06-15
CN112930195A (zh) 2021-06-08
ZA202102879B (en) 2022-10-26
BR112021008424A2 (pt) 2021-09-28
JPWO2020090892A1 (ja) 2021-09-24
JP7415939B2 (ja) 2024-01-17
WO2020090892A1 (ja) 2020-05-07
US20210388096A1 (en) 2021-12-16
JOP20210093A1 (ar) 2023-01-30
CN112930195B (zh) 2024-03-19
IL282650A (en) 2021-06-30
SG11202104463YA (en) 2021-05-28
MA54097A (fr) 2022-02-09
TW202035459A (zh) 2020-10-01
CA3117930A1 (en) 2020-05-07

Similar Documents

Publication Publication Date Title
MX2019012793A (es) Agentes anticuerpos dirigidos contra el gen de activación de linfocitos-3 (lag-3) y usos de los mismos.
CO2021005768A2 (es) Anticuerpo fn14 anti–humano
EA201791742A1 (ru) Антитела, направленные против гена-3 активации лимфоцитов (lag-3)
PE20191661A1 (es) Inhibidores de tgf beta1 isoforma-especificos contexto-permisivos y uso de los mismos
CR20180141A (es) Anticuerpos anti-cd 19 humano humanizados y métodos de utilización
CO6700829A2 (es) Moduladores novedosos y métodos de uso
PE20170665A1 (es) Anticuerpos anti-tau humanizados
AR105313A1 (es) Anticuerpo anti-cd137 terapéutico
EA201890640A1 (ru) Рекомбинантные векторы, содержащие пептид 2а
CU24568B1 (es) Anticuerpo inhibidor de masp-3
BR112019008859A2 (pt) anticorpos direcionados contra a morte programada 1 (pd-1)
CO2019012568A2 (es) Virus de la enfermedad de newcastle y usos de los mismos
EA202090800A1 (ru) Новые анти-cd3-эпсилон антитела
PE20181076A1 (es) Nuevos moduladores y metodos para su uso
PH12021550244A1 (en) Anti-btla antibody
CU20180129A7 (es) Anticuerpos anti-basigin humanizados
PE20220708A1 (es) Anticuerpos anti-cd73
BR112021021645A2 (pt) Anticorpos anti-hvem e uso dos mesmos.
CL2019003393A1 (es) Virus oncolíticos y método.
AR105541A1 (es) ANTICUERPOS MONOCLONALES ESPECÍFICOS PARA EL ANTÍGENO P DEL VIRUS RESPIRATORIO SINCICIAL HUMANO (VRSh), PRODUCIDOS Y SECRETADOS POR HIBRIDOMAS CELULARES, ÚTILES PARA LA DETECCIÓN Y EL DIAGNÓSTICO DE LA INFECCIÓN CAUSADA POR VRSh
MX2016008520A (es) Anticuerpo bdca-2 antihumano novedoso.
CL2017003309A1 (es) Métodos de purificación y/o inactivación viral
ZA202205288B (en) Humanized antibody and method for using the same
PE20180498A1 (es) Inmunoglobulinas conjugadas en cys80
CY1115897T1 (el) ΒΕΛΤΙΩΜΕΝΟ ΑΝΘΡΩΠΟΠΟΙΗΜΕΝΟ ΑΝΤΙΣΩΜΑ ΑΝΤΙ-ΑΝΘΡΩΠΙΝΗΣ ΙΝΤΕΓΓΡΙΝΗΣ α9